ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Oncolytics Biotech Inc

Oncolytics Biotech Inc (ONC)

1,31
0,21
(19,09%)
Fermé 20 Décembre 10:12PM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
1,31
Prix Achat
1,30
Prix Vente
1,31
Volume échangé
876 003
1,02 Fourchette du Jour 1,35
1,02 Plage de 52 semaines 2,08
Clôture Veille
1,10
Ouverture
1,07
Dernière Transaction
26
@
1.31
Dernière heure de transaction
Volume moyen (3 m)
133 994
Volume financier
-
VWAP
-

ONC Dernières nouvelles

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS PR Newswire BOSTON and SAN DIEGO and...

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...

Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor ...

CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Pr...

- Increased PD-L1 expression correlates with clinical response when pelareorep is combined with a proteasome inhibitor - - Data continue to recommend pelareorep as a standardized backbone for...

Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

CALGARY, Alberta and SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancrea...

CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Announces Attendance of Upcoming Conferences

CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference...

Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregul...

- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.18.264462809921.211.351.021874101.14989048CS
4-0.08-5.755395683451.391.41.021077871.22133874CS
120.18.264462809921.212.081.021339941.53299576CS
26-0.08-5.755395683451.392.081.02830911.48570899CS
52-0.42-24.27745664741.732.081.02734351.4992545CS
156-0.55-29.56989247311.864.491.02802242.24033806CS
260-1.04-44.25531914892.357.841.021326353.09139688CS

ONC - Frequently Asked Questions (FAQ)

What is the current Oncolytics Biotech share price?
The current share price of Oncolytics Biotech is $ 1,31
What is the 1 year trading range for Oncolytics Biotech share price?
Oncolytics Biotech has traded in the range of $ 1,02 to $ 2,08 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ONCOncolytics Biotech Inc
$ 1,30
(18,18%)
876k
SAUSt Augustine Gold and Copper Limited
$ 0,08
(14,29%)
272,8k
NEXTNextSource Materials Inc
$ 0,77
(11,59%)
854,79k
LIRCLithium Royalty Corp
$ 6,00
(11,11%)
56,45k
SBISerabi Gold Plc
$ 2,41
(10,55%)
11,7k
GRCGold Springs Resource Corp
$ 0,055
(-26,67%)
164,33k
DIAMStar Diamond Corporation
$ 0,02
(-20,00%)
7,48M
FTUUS Financial 15 Split Corp
$ 0,41
(-18,00%)
12,5k
XMF.AM Split Corp
$ 0,465
(-16,96%)
4k
FLNTFlint Corporation
$ 0,025
(-16,67%)
5k
CNQCanadian Natural Resources Ltd
$ 42,48
(-0,84%)
16,36M
DIAMStar Diamond Corporation
$ 0,02
(-20,00%)
7,48M
ENBEnbridge Inc
$ 58,57
(0,14%)
6,61M
TDToronto Dominion Bank
$ 74,25
(-0,74%)
6,25M
SUSuncor Energy Inc
$ 49,81
(-1,01%)
6,18M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock